Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Teva | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Teva

Revenues up 2% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva

3Q Revenues: $5.1 billion (+2%)

3Q Earnings: $706 million (loss of $84 million 3Q12)

YTD Revenues: $14.9 billion (-1%)

YTD Earnings: $876 million (-46%)

Comments: Generic revenues were flat in the quarter at $2.5 billion (including API sales of $162 million). U.S. revenues were $1.1 billion, up 6%. European revenues were $812 million, down 1%. ROW revenues were $533 million, down 11%, primarily due to foreign currency effects. Specialty medicines revenues were $2.1 billion, up 3%, primarily due to increased revenues of women’s health, oncology and respiratory medicines, as well as Azilect (+21% to $93 million), partially offset by lower revenues of Provigil (-58% to $22 million) and Nuvigil (-7% to $87 million). U.S. revenues were $1.5 billion, up 3%, European revenues of $426 million, up 12%. ROW revenues were $144 million, down 17%. OTC revenues were $286 million, up 13%, primarily due to higher sales of PGT Healthcare portfolio medicines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters